Search

Phenolsulfonphthalein

Phenolsulfonphthalein or otherwise called phenol red is a pH indicator commonly used in cell biology laboratories.

Felypressin

It is a non-catecholamine vasoconstrictor used in local anaesthetic injections for dental use, and is an ingredient of preparations that have been used for treatment of pain and inflammation of the mouth … A synthetic nonapeptide comprising cysteinyl, phenylalanyl, phenylalanyl, glutaminyl, asparaginyl, cysteinyl, prolyl, lysyl, and glycinamide residues in sequence, with a disulfide bridge joining the two

2-Undecanone

Vimseltinib

A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results in … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate

Cenisertib

Cenisertib is an aurora kinase inhibitor.

Amubarvimab

Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.

SGN-15

SGN-15 is studied in the treatment of cancer. It combines a monoclonal antibody with the anticancer drug doxorubicin. … Monoclonal antibodies are substances that are made in the laboratory and that can locate and bind to cancer cells. Doxorubicin is a type of anthracycline antitumor antibiotic.

Fosinoprilat

Fosinoprilat is the active phosphinic acid metabolite of prodrug [fosinopril], which is activated by esterases in vivo. It binds zinc with phosphinic acid group.

Oritavancin

[A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. … [L12858] Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections.

Umifenovir

[A191475] It has been in use in Russia for approximately 25 years and in China since 2006. … Umifenovir is an indole-based, hydrophobic, dual-acting direct antiviral/host-targeting agent used for the treatment and prophylaxis of influenza and other respiratory infections.